Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pantoprazole in neonates and preterm infants with GERD
NCT00362609Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2006
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of pantoprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Pfizer. Primary endpoint: Variance of Oral Bioavailability at 1 day. Started Jul 2006; status: completed.
02
Drugs
pantoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00362609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00362609.